ZURICH (Reuters) ? Swiss biotech company Actelion Ltd said on Tuesday a mid-stage study showed one of its drugs under development helped reduce new inflammatory brain lesions in a targeted group of multiple sclerosis patients.
The study found Actelion's Ponesimod drug, a selective S1P1 receptor agonist, achieved its primary trial goal of reducing the number of new active inflammatory lesions in the brain of patients with relapsing-remitting multiple sclerosis.
"This is the first report of a selective S1P1 receptor agonist reporting a statistically significant treatment effect in patients suffering from relapsing multiple sclerosis," said Martin Clozel, Actelion's managing director and chief scientific officer.
The achievement of its primary endpoints in the trial will allow Ponesimor to proceed to the final stage of clinical development, the company said.
Actelion is trying to cut its dependence on key drug Tracleer, which treats a rare heart and lung disorder and rakes in more than $1 billion a year, but said recently competition from rival drugs is hitting its U.S. sales.
In a separate release, the company said Joseph Scodari had resigned from the board for personal reasons.
olympia los angeles cy twombly cydia geocaching breastfeeding atmosphere
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.